论文部分内容阅读
目的观察岩舒注射液联合NP方案在晚期非小细胞肺癌(NSCLC)中的作用效果。方法将2006-5至2008-5就诊于我院的72例晚期非小细胞肺癌患者随机分为治疗组、对照组,各36例,治疗组给予岩舒注射液联合NP化疗方案治疗,对照组给予NP化疗方案化疗,观察化疗效果及化疗毒性反应变化。结果治疗组和对照组的总RR分别为38.9%和16.7%(P<0.05),总临床受益率(CBR)分别为75.0%和55.6%(P>0.05),治疗组消化道毒性反应及骨髓抑制均低于对照组(P<0.01)。结论岩舒注射液能增强晚期非小细胞肺癌(NSCLC)患者的化疗效果,降低毒性反应,提高生活质量。
Objective To observe the effect of Yan Shu injection and NP regimen in advanced non-small cell lung cancer (NSCLC). Methods 72 patients with advanced NSCLC treated in our hospital from May 2006 to May 2008 were randomly divided into treatment group (n = 36) and control group (n = 36). The treatment group was treated with Yan Shu injection combined with NP chemotherapy and the control group NP chemotherapy given chemotherapy, to observe the effect of chemotherapy and chemotherapy toxicity changes. Results The total RR of treatment group and control group were 38.9% and 16.7% respectively (P <0.05), and the total clinical benefit rates (CBR) were 75.0% and 55.6% (P> 0.05) Inhibition were lower than the control group (P <0.01). Conclusion Yanshu injection can enhance the chemotherapy effect of patients with advanced non-small cell lung cancer (NSCLC), reduce the toxic reaction and improve the quality of life.